On January 29, 2025 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported that clinical data for its 4-1BB agonist, ATOR-1017, has been published in the Journal for ImmunoTherapy of Cancer (JITC) (Press release, Alligator Bioscience, JAN 29, 2025, View Source [SID1234649919]). This publication validates ATOR-1017’s safety and tolerability in patients with advanced cancers and highlights early signs of clinical efficacy. Additionally, pharmacokinetic and pharmacodynamic analyses demonstrate proof of mechanism, further supporting the therapeutic potential of ATOR-1017.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This publication adds to previously published preclinical data and underscores the scientific foundation of ATOR-1017 as an immunotherapy designed to activate T cells and natural killer (NK) cells in a tumor-specific manner. These findings strengthen the clinical package for ATOR-1017 and support its potential for future development, particularly in combination with other anticancer agents.
Dr. Sumeet Ambarkhane, Chief Medical Officer of Alligator Bioscience, commented:
"These first-in-human clinical data of ATOR-1017 in the Journal for ImmunoTherapy of Cancer demonstrate excellent safety profile and biological activity ATOR-1017. This peer-reviewed publication also reaffirms the scientific value of targeting 4-1BB pathway as a cancer immunotherapy, and further enhances its potential for future development."
Alligator remains focused on advancing its lead candidate, mitazalimab, while exploring strategic opportunities to realize the potential of ATOR-1017.